WO2003034028A2 - Methods for identifying and using modulators of estrogen related receptor gamma - Google Patents
Methods for identifying and using modulators of estrogen related receptor gamma Download PDFInfo
- Publication number
- WO2003034028A2 WO2003034028A2 PCT/US2002/032917 US0232917W WO03034028A2 WO 2003034028 A2 WO2003034028 A2 WO 2003034028A2 US 0232917 W US0232917 W US 0232917W WO 03034028 A2 WO03034028 A2 WO 03034028A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- errγ
- compound
- compounds
- ligand
- hydroxytamoxifen
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/362—Menopause
Definitions
- Formulations suitable for topical administration in the mouth include lozenges comprising an ERR ⁇ ligand in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouth washes comprising the active ingredient in a suitable liquid carrier.
- the ERR ⁇ ligands of the present invention can be made up in solution or suspension in a suitable sterile aqueous or non-aqueous vehicle. Additives such as buffers (e.g. sodium metabisulphite or disodium edeate) and thickening agents such as hypromellose can also be included.
- compositions of the present invention comprising an ERR ⁇ ligand can also used in combination with other therapeutic agents.
- the amount of an ERR ⁇ ligand of the present invention required for use in treatment will of course vary not only with the particular ERR ⁇ ligand selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patients. Selection of such an amount, referred to herein as the "therapeutically effective amount or concentration" is ultimately at the discretion of the attending physician.
- suitable doses of pharmaceutical compositions of the present invention providing a therapeutically effective amount of an ERR ⁇ ligand will be in the range of from about 0.1 to 300 mg/kg of bodyweight per day, particularly from about 1 to 100 mg/kg of bodyweight per day.
- An appropriate dosage unit for oral administration generally contains from about 1 to about 250 mg, more preferably 25 to 250 mg of an ERR ⁇ ligand.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003536715A JP2005509628A (en) | 2001-10-16 | 2002-10-16 | Methods of identifying and using modulators of estrogen-related receptor gamma |
AU2002342058A AU2002342058A1 (en) | 2001-10-16 | 2002-10-16 | Methods for identifying and using modulators of estrogen related receptor gamma |
US10/491,677 US20050074765A1 (en) | 2002-10-16 | 2002-10-16 | Methods for identifying and using modulators of estrogen related receptor gamma |
EP02776223A EP1436395A4 (en) | 2001-10-16 | 2002-10-16 | Methods for identifying and using modulators of estrogen related receptor gamma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32988801P | 2001-10-16 | 2001-10-16 | |
US60/329,888 | 2001-10-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003034028A2 true WO2003034028A2 (en) | 2003-04-24 |
WO2003034028A3 WO2003034028A3 (en) | 2004-02-19 |
Family
ID=23287445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/032917 WO2003034028A2 (en) | 2001-10-16 | 2002-10-16 | Methods for identifying and using modulators of estrogen related receptor gamma |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1436395A4 (en) |
JP (1) | JP2005509628A (en) |
AU (1) | AU2002342058A1 (en) |
WO (1) | WO2003034028A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006130503A2 (en) * | 2005-05-27 | 2006-12-07 | Janssen Pharmaceutica N.V. | Errϝ peptide fragment complexes and uses thereof in drug discovery |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101631581B1 (en) * | 2010-06-11 | 2016-06-17 | 한국생명공학연구원 | FRET sensor fused nano-particles and detecting method for phytoestrogen using the same |
KR101579008B1 (en) * | 2013-09-25 | 2015-12-22 | 경북대학교 산학협력단 | ERR- A composition for preventing or treating retinopathy comprising an ERR- inhibitor and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096301A (en) * | 1986-10-10 | 2000-08-01 | Industria Farmaceutica Serono Spa | Combined interferon/antiestrogen therapy for treatment of breast cancer |
US6218128B1 (en) * | 1997-09-12 | 2001-04-17 | Allergan Sales, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
-
2002
- 2002-10-16 AU AU2002342058A patent/AU2002342058A1/en not_active Abandoned
- 2002-10-16 WO PCT/US2002/032917 patent/WO2003034028A2/en not_active Application Discontinuation
- 2002-10-16 EP EP02776223A patent/EP1436395A4/en not_active Withdrawn
- 2002-10-16 JP JP2003536715A patent/JP2005509628A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096301A (en) * | 1986-10-10 | 2000-08-01 | Industria Farmaceutica Serono Spa | Combined interferon/antiestrogen therapy for treatment of breast cancer |
US6218128B1 (en) * | 1997-09-12 | 2001-04-17 | Allergan Sales, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
Non-Patent Citations (3)
Title |
---|
COWARD P. ET AL.: '4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma' PROC. NATL. ACAD. SCI. USA vol. 98, no. 15, 17 July 2001, pages 8880 - 8884, XP002971442 * |
ROLLEROVA E. ET AL.: 'Intracellular estrogen receptors, their characterization and function' ENDOCR. REGUL. vol. 34, 2000, pages 203 - 218, XP002971443 * |
See also references of EP1436395A2 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006130503A2 (en) * | 2005-05-27 | 2006-12-07 | Janssen Pharmaceutica N.V. | Errϝ peptide fragment complexes and uses thereof in drug discovery |
WO2006130503A3 (en) * | 2005-05-27 | 2007-01-25 | Janssen Pharmaceutica Nv | Errϝ peptide fragment complexes and uses thereof in drug discovery |
US7655756B2 (en) | 2005-05-27 | 2010-02-02 | Johnson & Johnson Pharmaceutical Research & Development, Llc | Crystallized structure of estrogen related receptor gamma in complex with bisphenol A |
Also Published As
Publication number | Publication date |
---|---|
EP1436395A2 (en) | 2004-07-14 |
WO2003034028A3 (en) | 2004-02-19 |
AU2002342058A1 (en) | 2003-04-28 |
EP1436395A4 (en) | 2006-12-13 |
JP2005509628A (en) | 2005-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Higashijima et al. | The effect of activating ligands on the intrinsic fluorescence of guanine nucleotide-binding regulatory proteins. | |
Gearhart et al. | Monomeric complex of human orphan estrogen related receptor-2 with DNA: a pseudo-dimer interface mediates extended half-site recognition | |
Nilsson et al. | Estrogen receptor action | |
US7176277B2 (en) | Conversion of apoptotic proteins | |
Nygaard et al. | Structural modeling and electron paramagnetic resonance spectroscopy of the human Na+/H+ exchanger isoform 1, NHE1 | |
War et al. | Somatostatin receptor-3 mediated intracellular signaling and apoptosis is regulated by its cytoplasmic terminal | |
Hislop et al. | Desensitization and internalization of human and Xenopus gonadotropin-releasing hormone receptors expressed in αT4 pituitary cells using recombinant adenovirus | |
US6204067B1 (en) | Methods of identifying modulators of the estrogen receptor | |
CA2305711A1 (en) | Assays for nuclear receptor ligands using fret | |
Jisa et al. | Transcriptional activities of estrogen receptor alpha and beta in yeast properties of raloxifene | |
Devost et al. | Homo‐and hetero‐dimeric complex formations of the human oxytocin receptor | |
Mack et al. | GPR83 engages endogenous peptides from two distinct precursors to elicit differential signaling | |
Kuohung et al. | A high-throughput small-molecule ligand screen targeted to agonists and antagonists of the G-protein-coupled receptor GPR54 | |
US20220091120A1 (en) | Method for identifying modulators of g3bp activity | |
US7604959B2 (en) | Cell-based assays employing voltage and calcium dyes | |
Kunapuli et al. | Identification of small molecule antagonists of the human mas-related gene-X1 receptor | |
WO2003034028A2 (en) | Methods for identifying and using modulators of estrogen related receptor gamma | |
Emmerson et al. | Synthesis and characterization of 4, 4-difluoro-4-bora-3a, 4a-diaza-s-indacene (BODIPY)-labeled fluorescent ligands for the mu opioid receptor | |
US20050074765A1 (en) | Methods for identifying and using modulators of estrogen related receptor gamma | |
JP4206420B2 (en) | Inhibitors of nuclear protein / nuclear receptor interactions | |
Shimizu et al. | Amino‐Terminal Parathyroid Hormone Fragment Analogs Containing α, α‐di‐alkyl Amino Acids at Positions 1 and 3 | |
CA2234417A1 (en) | Human serum glucocorticoid regulated kinase, a target for chronic renal disease | |
US8927297B2 (en) | Methods to measure dissociation rates for ligands that form reversible covalent bonds | |
WO2002077169A2 (en) | Methods of detecting dissociated nuclear hormone receptor ligands | |
GB2371303A (en) | Receptor polypeptides with immunomodulatory activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10491677 Country of ref document: US |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003536715 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002776223 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002776223 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002776223 Country of ref document: EP |